NX
NXL.US Nexalin Technology Inc.
- Market cap
- USD 1.93M
- P/E
- -
- P/B
- 6.95x
- ROE
- -3,543.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NXL.US undervalued?
Graham numberThe Graham number of Nexalin Technology Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nexalin Technology Inc. fundamental analysis
No fundamental analysis for Nexalin Technology Inc. yet.
Nexalin Technology Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nexalin Technology Inc.
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use d…
Full company profileNexalin Technology Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nexalin Technology Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 207K | 243K | 144K | 1.32M | 111K | 169K | 302K | 141K |
| Gross Profit | -10.8K | 214K | 123K | 958K | 85.1K | 132K | 240K | -576K |
| Operating Income | -1.47M | -3.26M | -6.02M | -1.83M | -5.70M | -7.75M | -8.39M | -9.30M |
| EBITDA | -1.47M | -3.32M | -6.00M | -1.64M | -4.61M | -7.59M | -8.20M | -9.17M |
| Net Income | -5.02M | -3.40M | -6.08M | -1.70M | -4.65M | -7.61M | -8.22M | -9.33M |
| EPS | -21 | -14 | -25 | -6.99 | -19 | -25 | -15 | -12 |
| Balance Sheet | ||||||||
| Total Assets | 113K | 118K | 754K | 7.43M | 3.63M | 4.22M | 4.64M | 3.29M |
| Total Liabilities | 1.29M | 1.71M | 2.44M | 1.95M | 425K | 547K | 887K | 3.02M |
| Shareholders' Equity | -1.18M | -1.59M | -1.68M | 5.48M | 3.21M | 3.68M | 3.75M | 263K |
| Cash & Short-term Investments | 63.4K | 78.4K | 662K | 6.99M | 2.95M | 3.48M | 3.72M | 793K |
| Total Debt | 827K | 726K | 850K | 755K | 4.46K | - | - | 1.23M |
| Cash Flow | ||||||||
| Operating Cash Flow | -678K | -863K | -1.08M | -2.22M | -3.84M | -3.94M | -4.96M | -6.80M |
| Capital Expenditure | 4.00 | 648.00 | 1.00 | 1.00 | 109K | 170K | 96.9K | 190K |
| Free Cash Flow | -678K | -864K | -1.08M | -2.22M | -3.94M | -4.11M | -4.96M | -6.87M |
| Ratios | ||||||||
| ROE | - | - | - | -31.0% | -145.0% | -206.9% | -219.4% | -3,543.2% |
| ROA | -4,463.0% | -2,873.1% | -806.4% | -22.8% | -128.0% | -180.1% | -177.4% | -283.8% |
| Net Profit Margin | -2,421.2% | -1,401.1% | -4,218.9% | -128.5% | -4,197.6% | -4,508.7% | -2,725.8% | -6,638.8% |
| Debt to Equity | - | - | - | 0.14x | 0.00x | - | - | 4.66x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nexalin Technology Inc. dividends
Nexalin Technology Inc. has not paid dividends in the last 7 fiscal years.
Last stock split: 1:30 on Aug 31, 2026.
Who owns Nexalin Technology Inc.
- Insiders 14.27%
- Institutions 1.91%
- Public & others 83.82%
- Shares outstanding 1.24M
- Free float 661K
Top funds holding NXL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 3.17K | 0.30% | -0.03% | Sep 2026 |
| Fidelity Total Market Index | 567.00 | 0.05% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 553.00 | 0.05% | 0.00% | Sep 2026 |
Top institutions holding NXL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Geode Capital Management, LLC | 140K | 0.44% | -43.50% | Jun 2026 |
| Vanguard Capital Management, LLC | 127K | 0.40% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 65.5K | 0.21% | +523.19% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 51.4K | 0.16% | 0.00% | Jun 2026 |
| State Street Corp | 32.3K | 0.10% | 0.00% | Jun 2026 |
| UBS Group AG | 26.8K | 0.09% | +20.89% | Jun 2026 |
| Northern Trust Corp | 24.1K | 0.08% | 0.00% | Jun 2026 |
| Kovack Advisors Inc | 22.3K | 0.07% | -4.29% | Jun 2026 |
| StoneX Group Inc | 13.5K | 0.04% | -41.12% | Jun 2026 |
| Integrated Investment Consultants, LLC | 10.0K | 0.03% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 2.11K | 0.01% | -0.05% | Jun 2026 |
| Advisor Group Holdings, Inc. | 2.10K | 0.01% | 0.00% | Jun 2026 |
| Citigroup Inc | 1.46K | 0.00% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 1.00K | 0.00% | 0.00% | Jun 2026 |
| Mercer Global Advisors Inc. | 1.00K | 0.00% | 0.00% | Jun 2026 |
| Federation des caisses Desjardins du Quebec | 873.00 | 0.00% | 0.00% | Jun 2026 |
| Barclays PLC | 241.00 | 0.00% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 0.00 | 0.00% | -100.00% | Jun 2026 |
| FMR Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Renaissance Technologies Corp | 0.00 | 0.00% | -100.00% | Jun 2026 |
Nexalin Technology Inc. company profile
- Company name
- Nexalin Technology Inc.
- Ticker
- NXL.US
- Exchange
- USA Stocks
- Listed since
- Sep 16, 2022
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 8
- Fiscal year end
- December
- Address
- 1776 Yorktown, Houston, TX, United States, 77056
- Phone
- 832 260 0222
- Website
- nexalin.com
About Nexalin Technology Inc.
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.
Nexalin Technology Inc. management
4- Mr. Mark WhitePresident, CEO & Director · born 1962
- Dr. David Owens M.D.Chief Medical Officer, Member of Scientific Advisory Board & Director · born 1962
- Mr. John Patrick ClaudeCo-Founder and Director of Engineering & Development
- Mr. Justin Van Fleet CPAChief Financial Officer · born 1981